drugset / Trial / NCT02581839
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
NaSingle-groupOpen-labelTreatment
Summary
Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for use in patients with metastatic breast cancer but the effect it may or may not have on brain metastases has not been studied.
Timeline
- Start
- 2015-11-17
- Primary completion
- 2018-07-02
- Completion
- 2020-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 8 mg | Oral |
| Background | Ondansetron | Other / unclassified | 8 mg | Oral |